Sitc 2024 Ak132. Ak132 efficiently binds to cldn18.2 and cd47, exerting antitumor effects through multiple mechanisms; Why is targeting cd47 important?

China’s bispecific antibody specialist akeso is taking two more such molecules into phase 1. Ak132 is an asymmetric bispecific antibody with a “1+1” valency, designed to simultaneously target and block cldn18.2 and cd47.